Irish Residential Props Stock (OTC: RSHPF)

Latest news for Irish Residential Props (OTC:RSHPF) Stock

Irish Residential Properties REIT PLC is a Real Estate Investment Trust that focuses on acquiring, holding, managing, and developing investments focused on residential rental accommodations in Ireland. The group operates in one business segment, namely property investment.

IRISH RESIDNTL PPTYS REIT by Irish Residential Properties REIT PLC

Irish Residential Properties REIT PLC

News

JBLU

JetBlue CEO Says It Is Imperative We Keep Our Costs Low; Cannot Continue To Invest In Capital-intensive Assets That Must Be Financed Upon Delivery & Are Subsequently Unable To Produce A Return

Evercore ISI Group analyst Peter Levine maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Outperform and lowers the price target from $350 to $325.

Price Target

Analyst Ratings

CRWD

Evercore ISI Group Maintains Outperform on CrowdStrike Holdings, Lowers Price Target to $325

Loop Capital analyst Alan Gould maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Buy and lowers the price target from $139 to $130.

Loop Capital Maintains Buy on Walt Disney, Lowers Price Target to $130

WIIM

VBIV

VBI Vaccines shares are trading lower after the company was granted protection under Canada's CCAA by the Ontario Superior Court. The company received approval for a DIP loan, and Ernst & Young was appointed as the monitor during the restructuring process.

Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) shares are trading lower after it&nbsp;reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b40032647/xylem-reports-second-quarter-2024-results-and-raises-full-year-guidance" rel="noreferrer noopener">second-quarter FY24 results</a>.
Revenue grew 26% Y/Y to $2.17 billion (+9% organically), beating the consensus of $2.145 billion on strong execution and demand.
By segment, Measurement &amp; Control Solutions revenue was $482 million (+26% Y/Y), Water Infrastructure revenue was $631 million (+22% Y/Y), Applied Water revenue was $456 million (-5% Y/Y) and Water Solutions and Services was $600 million (+76% Y/Y).
Orders were up 12% Y/Y on a reported basis and declined 1% Y/Y organically to $2.09 billion.
The adjusted EBITDA margin reached 20.8%, up 170 basis points Y/Y, driven by productivity savings, higher volume, and price increases, which outweighed the effects of inflation, strategic investments, and mix changes.
Adjusted EPS was $1.09 (+14% Y/Y),&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $1.05</a>.&nbsp;
Operating cash flow for six months ended June 30 stood at $377 million, compared to $9 million a year ago.
The company exited the year with cash and cash equivalents worth $815 million.&nbsp;
Outlook: For FY24, Xylem raised the adjusted EPS&nbsp;outlook&nbsp;from&nbsp;$4.10-$4.25&nbsp;to&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$4.18-$4.28 (versus the consensus of&nbsp;$4.21)</a>.
Also, the company revised its FY24 revenue outlook to $8.55 billion (consensus $8.56 billion), marking an increase of 16% Y/Y, with organic revenue growth expected to be 5%–6%, up from the previous range of 4%–6%.
Xylem&#8217;s President and CEO, Matthew Pine, said, &#8220;Healthy demand, combined with the team&#8217;s disciplined operational execution, delivered significant margin expansion in the quarter. Evoqua integration and synergies are also well on track.&#8221;
&#8220;We are confident in the team&#8217;s commitment to realizing our operational potential, and underlying demand in our largest markets remains resilient despite likely macro variability in the second half. Our diversified portfolio of mission-critical solutions is ideally positioned to meet global demand from intensifying water challenges.&#8221;
Investors can gain exposure to the stock via Global X Clean Water ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQWA#NASDAQ">AQWA</a>) and Invesco S&amp;P Global Water Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGW#NYSE">CGW</a>).
Price Action: XYL shares are down 3% to $137.29 at the last check Tuesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Earnings

Equities

Large Cap

Guidance

Movers

AQWA

Xylem's Water Wisdom Pays Off: Q2 Beats Estimates, Outlook Upgraded

NEOG

Neogen shares are trading higher after the company reported better-than-expected Q4 revenue results.

Stephens &amp; Co. analyst Mike Scialla maintains Chesapeake Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHK#NASDAQ">CHK</a>) with a Equal-Weight and raises the price target from $117 to $118.

Stephens & Co. Maintains Equal-Weight on Chesapeake Energy, Raises Price Target to $118

Craig-Hallum analyst Greg Palm maintains Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) with a Buy and lowers the price target from $54 to $45.

Craig-Hallum Maintains Buy on Symbotic, Lowers Price Target to $45

Loop Capital analyst Alton Stump maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Buy and lowers the price target from $357 to $342.

Loop Capital Maintains Buy on McDonald's, Lowers Price Target to $342

Eagle Materials shares are trading higher after the company reported better-than-expected Q1 EPS results.

Stephens &amp; Co. analyst Terry McEvoy maintains Byline Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BY#NYSE">BY</a>) with a Equal-Weight and raises the price target from $27 to $29.

Stephens & Co. Maintains Equal-Weight on Byline Bancorp, Raises Price Target to $29

LGIH

LGI Homes shares are trading higher after the company reported better-than-expected Q2 EPS results.

Trading Ideas

VBI Vaccines Shares Resume Trade

B of A Securities analyst Craig Siegenthaler upgrades LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) from Neutral to Buy and announces $268 price target.

Upgrades

LPLA

B of A Securities Upgrades LPL Finl Hldgs to Buy, Announces $268 Price Target

JetBlue Airways CEO Says Our Revenue Growth Has Not Been Enough To Outpace Our Cost Challenges; Pratt & Whitney Engine Related Aircraft Groundings Are Significantly Impeding Our Growth Rate, Pressuring Our Profitability

Phillips 66 shares are trading higher after the company reported better-than-expected Q2 financial results.

As of July 30, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Verona Pharma PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>)</h3>
<ul>
<li>Verona Pharma will report its financial results for the second quarter on Thursday, Aug. 8. The company's stock gained around 46% over the past month and has a <a href="https://www.benzinga.com/quote/VRNA">52-week high of</a> $23.72.</li>
<li>RSI Value: 71.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>VRNA Price Action: Shares of Verona Pharma fell 0.5% to close at $22.61 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Catalyst Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>)</h3>
<ul>
<li>On July 24, Catalyst Pharmaceuticals entered into an exclusive license, supply and commercialization agreement with Kye Pharmaceuticals for AGAMREE&#xAE; in Canada. &#8220;We are pleased to enter into this agreement with Kye Pharmaceuticals for AGAMREE, marking a pivotal milestone in our strategic initiative to expand the product&#8217;s footprint in North America. This collaboration leverages our combined expertise, fortifies our alliance by licensing our second therapeutic rare disease product for Canada, and demonstrates our sustained commitment to patient care,&#8221; stated Richard J. Daly, CEO and President of Catalyst. The company's stock gained around 11% over the past month and <a href="https://www.benzinga.com/quote/CPRX">has a 52-week high</a> of $17.99.</li>
<li>RSI Value: 70.99</li>
<li>CPRX Price Action: Shares of Catalyst Pharmaceuticals fell 0.6% to close at $17.48 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Viridian Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>)</h3>
<ul>
<li>On July 29, Wedbush maintained an Outperform rating on the stock and reiterated its price target of $42. The company's stock gained around 31% over the past month and has a <a href="https://www.benzinga.com/quote/VRDN">52-week high</a> of $24.18.</li>
<li>RSI Value: 73.86</li>
<li>VRDN Price Action: Shares of Viridian Therapeutics gained 3.8% to close at $17.29 on Monday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40009447/roblox-morgan-stanley-and-2-other-stocks-insiders-are-selling">Roblox, Morgan Stanley And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Short Ideas

Markets

CPRX

VRDN

VRNA

Top 3 Health Care Stocks You May Want To Dump This Quarter

Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) will release its third quarter financial results, after the <a href="https://www.benzinga.com/quote/SBUX/earnings">closing bell on Tuesday, July 30.</a>
Analysts expect the Seattle, Washington-based company to report quarterly earnings at 93 cents per share, down from $1 per share in the year-ago period. Starbucks expects to post revenue of $9.24 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
According to a recent WSJ report, Elliott Investment Management has taken a significant stake in the coffee giant.
Starbucks shares gained 1.5% to close at $75.14 on Monday.
Benzinga readers can access the latest analyst ratings on the<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie"> Analyst Stock Ratings </a>page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/592423ce290fa700011180e0/jon-tower">Citigroup analyst Jon Tower</a> maintained a Neutral rating and cut the price target from $85 to $80 on July 22. This analyst has an accuracy rate of 71%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5df37c17bffdfc0001d738fc/brian-mullan">Deutsche Bank analyst Brian Mullan</a> maintained a Hold rating and slashed the price target from $89 to $85 on July 16. This analyst has an accuracy rate of 75%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587e33185064ed0001730304/john-ivankoe">JP Morgan analyst John Ivankoe</a> maintained an Overweight rating and cut the price target from $92 to $90 on July 10. This analyst has an accuracy rate of 72%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5df37c17bffdfc0001d738fc/brian-mullan">Piper Sandler analyst Brian Mullan</a> maintained a Neutral rating and lowered the price target from $88 to $85 on May 6. This analyst has an accuracy rate of 75%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/653645581c7d4600012cd535/meredith-jensen">HSBC analyst Meredith Jensen</a> maintained a Hold rating and cut the price target from $107 to $84 on May 3. This analyst has an accuracy rate of 71%.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40011827/more-than-4m-bet-on-appian-check-out-these-3-stocks-insiders-are-buying">More Than $4M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying</a></li>
</ul>

SBUX

Starbucks Likely To Report Lower Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Biotech

General

Merck Exec Says Targeting Next Year's RSV Season In U.S. For RSV Antibody

U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 200 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.50% to 40,742.44 while the NASDAQ slipped 0.01% to 17,370.07. The S&amp;P 500 also rose, gaining, 0.22% to 5,475.80.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40036066/top-3-financials-stocks-which-could-rescue-your-portfolio-for-july">Top 3 Financials Stocks Which Could Rescue Your Portfolio For July</a>
Leading and Lagging Sectors Financials shares jumped by 1.3% on Tuesday.
In trading on Tuesday, consumer staples shares fell by 1%.
Top Headline
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) reported better-than-expected second-quarter financial results.
Pfizer reported second-quarter adjusted EPS of 60 cents, down 11% year over year, beating the consensus of 46 cents. The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion.
Pfizer updated its 2024 revenue forecast to $59.5 billion—$62.5 billion, compared to prior guidance of $58.5 billion—$61.5 billion and consensus of $60.7 billion. Pfizer expects 2024 adjusted EPS of $2.45-$2.65 compared to prior guidance of $2.15-$2.35 and consensus of $2.37.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares shot up 158% to $3.0500 after the company announced topline results from its Phase 2 OVATION 2 study with IMNN-001. The results showed an 11.1-month improvement in median overall survival compared to standard-of-care alone in the intent-to-treat population.</li>
<li>Shares of Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) got a boost, surging 100% to $0.1766. AGAPE ATP strengthened wellness division via innovative incubation with emerging local SMEs.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares were also up, gaining 44% to $2.44 after the company announced FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.</li>
</ul>
Equities Trading DOWN
<ul>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares dropped 79% to $12.37. This sudden decline was triggered by the registration of two private placements with the U.S. Securities and Exchange Commission, which unlocked millions of shares and led to increased selling pressure, Bloomberg reported on Tuesday.</li>
<li>Shares of NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) were down 35% to $10.78. NIP Group announced the closing of its initial public offering and partial exercise of underwriters' option to purchase additional ADSs.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) was down, falling 31% to $0.7169 after the company announced it entered into an exclusive license agreement with Cortice Biosciences.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40036664/jim-cramer-says-no-to-this-health-care-stock-recommends-holding-on-to-constellation-ener">Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: &#8216;It&#8217;s Up A Huge Amount&#8217;</a>
Commodities In commodity news, oil traded down 1.3% to $74.81 while gold traded up 0.5% at $2,438.40.
Silver traded up 1% to $28.145 on Tuesday, while copper fell 0.9% to $4.0485.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.7%, Germany's DAX gained 0.7% and France's CAC 40 climbed 0.7%. Spain's IBEX 35 Index rose 0.9%, while London's FTSE 100 fell 0.1%.
The Euro Area GDP grew by 0.3% on quarter during the second quarter, the same as in the prior period but above expectations of 0.2%. The economic sentiment indicator in the Eurozone slipped to 95.8 in July from 95.9 in the prior month, while services sentiment indicator fell to 4.8 in July from a revised 6.2 in the prior month.
The German economy shrank 0.1% on quarter during the second quarter, compared to a 0.2% increase in the prior quarter, while Spanish economy expanded by 0.8% quarter-over-quarter in the second quarter. The French economy grew by 0.3% quarter-over-quarter during the second quarter.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.15%, Hong Kong's Hang Seng Index dipping 1.37%, China's Shanghai Composite Index falling 0.43% and India's S&amp;P BSE Sensex rising 0.12%.
Japanese unemployment rate came in at 2.5% for June, versus market projections of 2.6%.
Economics
<ul>
<li>The number of job openings came in at 8.184 million in June compared to a revised 8.23 million in May.</li>
<li>The S&amp;P CoreLogic Case-Shiller 20-city home price index rose 6.8% year-over-year in May versus a revised 7.3% gain in April.</li>
<li>The FHFA house price index came in unchanged for May.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40036623/wall-streets-most-accurate-analysts-weigh-in-on-3-industrials-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 4% Dividend Yields</a></li>
</ul>

Eurozone

Commodities

ATPC

CNSP

IMNN

NIPG

PCSA

Dow Jumps 200 Points; Pfizer Earnings Top Views

Canadian Apartment Properties: Keep Your Stick On The Ice

CDPYF

EREUF

RSHPF

Irish Residential Props

Berenberg upgrades Irish Residential Props (OTC:<a class="ticker" href="/stock/RSHPF#OTC">RSHPF</a>) from Hold to Buy.

Berenberg Upgrades Irish Residential Props to Buy

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Irish Residential Props

News

Latest news for Irish Residential Props (OTC:RSHPF) Stock

Tuesday, March 02, 2021